公开(公告)号：US09279156B2

公开(公告)日：2016-03-08

申请号：US14109163

申请日：2013-12-17

Applicant: Myriad Genetics, Inc.

Inventor： Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

IPC: C12Q1/68 ,  G06F19/22

CPC classification number: C12Q1/6827 ,  C12Q1/6858 ,  C12Q1/6874 ,  C12Q1/6883 ,  G06F19/22 ,  C12Q2535/122 ,  C12Q2537/143

Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.

Abstract translation: 提供了使用核酸测序检测等位基因不平衡的方法和系统。

公开(公告)号：US20150080260A1

公开(公告)日：2015-03-19

申请号：US14554715

申请日：2014-11-26

Applicant: Myriad Genetics, Inc.

Inventor： Victor Abkevich ,  Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q1/6827 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G16B20/00 ,  C12Q2537/16

Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

Abstract translation: 本文件提供了评估样品（例如癌细胞）中存在杂合性（LOH）特征丧失的方法和材料。 例如，提供了用于确定细胞（例如，癌细胞）是否包含LOH标记的方法和材料。 还提供了用于鉴别具有同源性定向修复（HDR）缺陷的细胞（例如癌细胞）的材料和方法以及用于鉴定可能对特定癌症治疗方案作出反应的癌症患者的材料和方法。

公开(公告)号：US20150018527A1

公开(公告)日：2015-01-15

申请号：US14307708

申请日：2014-06-18

Applicant: Myriad Genetics, Inc.

Inventor： Victor Abkevich ,  Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  A61K31/282 ,  A61K33/24 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.